EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Sign up for free to view them and see the most relevant paragraphs highlighted.
Case C-121/17: Reference for a preliminary ruling from the High Court of Justice (Chancery Division) (United Kingdom) made on 8 March 2017 — Teva UK Ltd, Accord Healthcare Ltd, Lupin Ltd, Lupin (Europe) Ltd, Generics (UK) trading as ‘Mylan’ v Gilead Sciences Inc.
ECLI:EU:UNKNOWN:62017CN0121
62017CN0121
March 8, 2017
With Google you find a lot.
With us you find everything. Try it now!
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
15.5.2017
Official Journal of the European Union
C 151/21
(Case C-121/17)
(2017/C 151/28)
Language of the case: English
Referring court
Parties to the main proceedings
Applicants: Teva UK Ltd, Accord Healthcare Ltd, Lupin Ltd, Lupin (Europe) Ltd, Generics (UK) trading as ‘Mylan’
Defendant: Gilead Sciences Inc.
Question referred
What are the criteria for deciding whether ‘the product is protected by a basic patent in force’ in Article 3(a) of Regulation No. 469/2009 (1)?
* Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009, L 152, p. 1).
Language of the case: English
* * *
EurLex Case Law
AI-Powered Case Law Search
Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly
Get Instant Answers to Your Legal Questions
Cancel your subscription anytime, no questions asked.Start 14-Day Free TrialAt Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.